Varicella Vaccine has been approved in the European Union and in the Other Countries

Studies listed may include approved and non-approved uses, formulations or treatment regimens. Before prescribing any product mentioned in this Register, healthcare Professionals should consult prescribing information approved in their country (view UK and US information for Healthcare Professionals).

The summaries are in PDF format. If you do not have Adobe® Acrobat® Reader™ installed, you can download it for free.


Varicella Vaccine studies

Select the study ID number to view the trial summary

Study IDPhaseTitle
208133/161 (OKAH-161) IV A controlled clinical study to assess the immunogenicity and reactogenicity of SmithKline Beecham Biologicals’ varicella vaccine in children aged between 1 and 12 years with a known history of neurodermatitis. SmithKline Beecham Biologicals is currently GlaxoSmithKline Biologicals.
208133/178 (OKA-178) III A phase III, open-label, multi-centre study to assess the immunogenicity and safety of GlaxoSmithKline Biologicals’ live attenuated varicella vaccine (VARILRIX?), given as a primary vaccination at 4.5 months and 6.5 months post-transplantation, in autologous stem cell/ bone marrow transplant recipients aged 18 years and older. Varilrix™ (OKAH): GlaxoSmithKline (GSK) Biologicals’ live attenuated varicella vaccine
763310/001 II A phase I/II trial of an investigational vaccination regimen in infants.
101501 I An exploratory, open, randomized, phase I-II study to evaluate the safety and the immune responses to VZV induced by an investigational vaccination regimen or a live attenuated OKA VZV vaccine in adult subjects aged 18-30 years and in adult subjects aged 50-70 years. Varilrix™ (OKA VZV): GlaxoSmithKline Biologicals’ live attenuated OKA strain Varicella vaccine